

Programme

Note: Programme timings, lecture titles and speakers may be subject to change without notice

THURSDAY 19th NOVEMBER 2026		
08.15 - 08.45	REGISTRATION	
08.45 - 09.00	WELCOME AND INTRODUCTION BY THE PRESIDENT OF THE BSTP – Peter Clements <i>Session Chair: Peter Clements</i>	
09.00 - 09.45	Update on the pathology and pathogenesis of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) <i>Prof. Tim Kendall</i> <i>The University of Edinburgh, UK</i>	
09.45 - 10.30	Translational modelling of human MASLD and leveraging real-world data <i>Prof. Tim Kendall</i> <i>The University of Edinburgh, UK</i>	
10.30 - 11.00	REFRESHMENT BREAK AND POSTER SESSION	
	Session 2: <i>Session Chair: Aleksandra Zalewska</i>	
11.00 - 11.45	"Translational animal models of human kidney disease - fact or folly?" Part 1 <i>Dr. Magnus Söderberg</i> <i>AstraZeneca, Sweden</i>	
11.45 - 12.30	"Translational animal models of human kidney disease - fact or folly?" Part 2 <i>Dr. Magnus Söderberg</i> <i>AstraZeneca, Sweden</i>	
12.30 - 13.30	LUNCH	
13.30 - 14.00	<i>Scientific Organiser of Mouse Pathology Workshop: Dr Ellie Herbert TBC</i> Mouse necropsy <i>Dr Ellie Herbert</i>	<i>Session Chair: Stephen Drew</i> 13.30 – 14:15 Title: Off-Target Profiling to Enhance Preclinical Assessment of Biologics <i>Susann Busch</i> <i>Astrazeneca, Sweden</i>
14.00 - 14.30	Creating pathology data	
14.30 - 15.00	Histology Basics Anna MacDonald	14:15-15:00 Title: TBC (Tissue cross reactivity) <i>Paul Edwards</i> <i>Labcorp, UK</i>
15.00 - 15.30	REFRESHMENT BREAK	
15.30 - 16.15	<i>Session Chair: Mark Arends</i> Recognising common background lesions in different strains of mice	<i>Session Chair: Jon Carter</i> Title: TBC (Membrane protein arrays) <i>Mark Aspinall-O'Dea</i> <i>Retrogenix, Charles River Laboratories, UK</i>
16.15 - 17.00	Common causes of unexpected death (in research mice)	Title: TBC (Target validation) <i>Deon Hildebrand</i> <i>GSK, UK</i>
17.00 – 18.00	BSTP Annual General Meeting	
18.00 onwards	Drinks and Canapé Reception	

FRIDAY 20th NOVEMBER 2026	
08.30 - 08.55	REGISTRATION
08.55 - 09.00	INTRODUCTION TO DAY 2 <i>Session Chair: Giovanni Pellegrini</i>
09.00 - 9.45	Title: TBC
9.45 - 10.30	Unique Challenges underlying Core Concepts in Neuropathology Evaluations <i>Dr Deepa B Rao</i> <i>Greenfield Pathology Services, USA</i>
10.30 - 11.00	REFRESHMENT BREAK
11.00 - 11.45	Engineered GEMMs for Pharma: Pathology-Driven Models to Power Target Validation and Therapeutic Development <i>Dr Michelle Porritt</i> <i>AstraZeneca, Sweden</i>
11.45 -12.00	<i>Short talk sponsor</i>
12.00 - 13.00	LUNCH
13.00 - 13.45	<i>Session Chair: Clare Hoover (TBC)</i> <i>In search of the 'perfect' model: Mammary tumorigenesis across species.</i> <i>Prof. Kate Hughes</i> <i>University of Cambridge, UK</i>
13.45 - 14.30	<i>Antibody-based therapeutics for targeting the tumour stroma and sarcomas</i> <i>Prof. Clare Isacke</i> <i>The Institute of Cancer Research, UK</i>
14.30 - 15.00	REFRESHMENT BREAK
15.00 - 15.45	<i>Title: TBC (GEMMs for pancreatic cancer)</i> <i>Prof. Jen Morton</i> <i>CRUK Scotland Institute/University of Glasgow, UK</i>
15.45 - 16.00	CONCLUDING REMARKS BY THE NEW PRESIDENT OF THE BSTP –